Onesource Specialty Pharma Ltd.
ONESOURCE · NSE · Healthcare
With a 20% margin of safety, our buy-below price is ₹2,884.31. Low-confidence estimate — limited data.
Piotroski F-score 4/9 — quality of earnings & balance sheet.
Investability checklist
- ✕ROE above 15%-1.3%
- ✓Low debt (D/E < 0.5)0.26x
- ✕Positive free cash flow
- ✕Revenue growth > 10%1%
- ✕Earnings growing-95%
- ✕Net margin ≥ 10%-5.2%
- ✕Current ratio > 1.50.99
- ✓Below our fair value
- ✓Margin of safety ≥ 20%
- ✕Above 200-day average
- ✕Above 50-day average
- –Positive 1-year return
- ✓Altman Z in safe zoneZ 4.55
- ✕Piotroski ≥ 74/9
1-year price
EOD · 2026-06-15Our scores
Key fundamentals
SWOT snapshot
Strengths
- •Lightly leveraged balance sheet.
- •Financially solid — Altman Z 4.55.
Weaknesses
- •Low return on equity (-1.3%).
- •Price below its 200-day moving average (downtrend).
Opportunities
- •Trading in our value buy zone versus sector peers.
- •Trades ~122% below our estimated fair value.
Threats
- •Earnings contracting year on year.
About Onesource Specialty Pharma Ltd.
OneSource Specialty Pharma Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biological drug products in various injectable formats in India, Ireland, the United States, and internationally. The company provides end-to-end contract development and manufacturing operations (CDMO) services across various phases of preclinical and clinical development and commercial supply of biologics. It also offers drug-devices,
More in Healthcare
Our verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.